COMPANY PROFILE

MEDIWOUND: INNOVATING SOLUTIONS FOR WOUND AND BURN CARE

MEDIWOUND IS A BIOTECH COMPANY FOCUSED ON ADDRESSING UNMET NEEDS IN THE FIELDS OF BURNS AND CHRONIC/ HARD-TO-HEAL WOUND MANAGEMENT. MEDIWOUND DEVELOPS, MANUFACTURES AND COMMERCIALIZES INNOVATIVE MEDICINES AND MEDICAL DEVICES, TARGETED AT PROVIDING EFFECTIVE, SAFE AND EASY-TO-USE SOLUTIONS FOR PATIENTS WITH DEBILITATING AND/ OR LIFE-THREATENING SKIN AND SOFT-TISSUE CONDITIONS.

MEDIWOUND'S PLATFORM

MediWound's goal is to support healthcare professionals, by providing them with innovative, minimally invasive, safe and effective medicines and medical devices, for the treatment of patients who suffer from burns and hard-to-heal wounds.

MediWound is led by an experienced management team and an accomplished board of directors. The combination of their skills and capabilities support the enterprise through all stages, from early product research and clinical development to commercial success.

Supported by one of the largest investment groups in Israel, Clal Biotechnology Industries, MediWound has built a state-of-the-art, ISO 13485 compliant, EMA cGMP certified, sterile production facility that is the foundation of its independent commercial capabilities.

To learn more about MediWound Ltd visit:
www.mediwound.com
info@mediwound.com

MediWound Ltd.

MEDIWOUND'S INNOVATIVE PRODUCTS

THE MEDIWOUND PLATFORM CURRENTLY SUPPORTS TWO INNOVATIVE EU-APPROVED PRODUCTS. BOTH PRODUCTS ARE PROTECTED BY INTELLECTUAL PROPERTY RIGHTS AND THEIR REGISTRATION FILES ARE READY FOR SUBMISSION IN ROW MARKETS.

NexoBrid™

Effective Burn Eschar Removal for Better-Informed Treatment Decisions

MediWound's flagship drug product, NexoBrid, is indicated for the removal of eschar in adults with deep partial- and full-thickness thermal burns - a process also known as debridement.

NexoBrid removes the eschar without harming viable tissue in the majority of cases, after only a single 4-hour topical application at the patients' bedside. This early, non-surgical, eschar removal, can allow the physician to reach better diagnosis of burn-depth and an informed decision on further treatment, simply by direct visual assessment of the debrided clean wound bed. Furthermore, NexoBrid's effective eschar removal can significantly reduce the extent of surgery required without compromising healthy tissues.

NexoBrid contains a mixture of enzymes called "concentrate of proteolytic enzymes enriched in bromelain", which is extracted from the stem of the pineapple plant. It was studied by more than 100 leading burn specialists worldwide in 6 clinical studies involving more than 550 patients. In December 2012, NexoBrid received a European Marketing Authorization. Additional multi-national studies are planned to commence in 2013.

Currently NexoBrid is not marketed in Denmark. For additional information on the product, please consult the EMA approved wording of the SmPC and provided publications.

PolyHeal™

Help the Body Help Itself by Dechronifying Hard-to-Heal Wounds

PolyHeal is a CE marked, class IIb medical device that is approved for the treatment of chronic and hard-to-heal wounds of various etiologies, including severe wounds with exposed bone and tendons, ligaments and/or foreign material, post-operative and post-traumatic wounds, diabetic foot ulcers, and wounds in co-morbid patients.

PolyHeal is based on proprietary Negatively Charged Microspheres (NCM) technology and consists of sterile, negatively charged, non-biodegradable, synthetic microspheres, suspended in a serum-free nutrient medium. This unique device serves as a temporary matrix that enhances and expands the contact surface, to which a variety of cells and biological macromolecules, involved in the wound healing process, can non-selectively attach and create the environment for tissue regeneration.

PolyHeal is applied onto the wound by means of easy-to-use, sterile drops, facilitating wound healing by promptly creating healthy granulation coverage and reduction in wound size. It can be easily applied by physicians, nurses, wound care providers, family members or the patients themselves, both in an in-patient or out-patient setting. It has been successfully studied by more than 80 wound specialists in 5 clinical programs involving more than 500 patients, and has shown efficacy, positive long-term outcomes and a good safety and tolerability profile.

To learn more about MediWound Ltd visit:
www.mediwound.com
info@mediwound.com

MediWound Ltd.